文献速递冠心病

冠状动脉旁路移植术中大隐静脉桥血管外部支撑的随机临床试验

External Support for Saphenous Vein Grafts in Coronary Artery Bypass Surgery: A Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2022-01-01

本研究为一项患者内随机、开放标签、多中心试验,纳入224例多支冠状动脉病变行单纯搭桥手术的患者,每例患者的两根静脉桥血管随机接受外部支撑或无支撑,主要终点为12个月时血管内超声评估的内膜增生面积。

要点

  • 外部支撑装置未显著减少12个月静脉桥血管内膜增生面积。
  • 敏感性分析中支撑组内膜增生面积显著低于无支撑组。
  • 12个月死亡及主要心脑血管事件发生率与其他搭桥试验相似。

核心结论

  • 支撑与无支撑静脉桥血管12个月内膜增生面积差异未达统计学显著性。
  • 需进一步研究外部支撑装置对长期桥血管通畅率和临床结局的影响。

研究设计与样本

  • 患者内随机、开放标签、多中心研究,在北美17个心胸外科临床试验网络中心开展。
  • 2018年1月至2019年2月纳入224例多支冠状动脉病变行单纯搭桥手术的患者。
  • 每例患者的两根静脉桥血管随机分配至外部支撑或无支撑。

主要发现

  • 224例患者平均年龄65.8(标准差8.3)岁,178例(79.5%)为男性。
  • 203例(90.6%)符合血管内超声评估条件,其中85例(41.9%)在12个月时至少一根研究桥血管闭塞或严重病变(支撑组55例,无支撑组56例)。
  • 12个月内5例(2.2%)死亡,16例(7.1%)发生主要心脑血管事件。

临床怎么用

  • 对于行冠状动脉旁路移植术的多支病变患者,外部支撑装置在12个月时未显著减少静脉桥血管内膜增生。
  • 需结合长期通畅率和临床结局进一步评估该装置的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Intimal hyperplasia and subsequent saphenous vein graft failure may have significant adverse clinical effects in patients undergoing coronary artery bypass surgery. External support of saphenous vein grafts has the potential to prevent vein graft dilation and hence slow the rate of intimal hyperplasia and increase long-term vein patency. OBJECTIVE: To determine efficacy, as measured by intimal hyperplasia, and safety of an external saphenous vein graft support device in patients undergoing a coronary bypass graft procedure. DESIGN, SETTING, AND PARTICIPANTS: This within-patient randomized, open-label, multicenter study was conducted at 17 Cardiothoracic Surgical Trials Network centers in North America. Between January 2018 and February 2019, 224 patients with multivessel coronary artery disease undergoing isolated bypass surgery were enrolled. For each patient, 1 of 2 vein grafts was randomized to receive external support or no support. INTERVENTIONS: External vein graft support or no support. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was intimal hyperplasia area assessed by intravascular ultrasound at 12 months postrandomization for each study graft. Secondary confirmatory end points were lumen diameter uniformity assessed by angiography and graft failure (≥50% stenosis) by quantitative coronary angiography. Major cardiac and cerebrovascular events were collected through month 12. RESULTS: Among 224 patients (mean [SD] age, 65.8 [8.3] years; 178 [79.5%] male), 203 (90.6%) were eligible for intravascular ultrasound, of which 85 (41.9%) had at least 1 study graft occluded or severely diseased at 12 months (55 supported, 56 unsupported). After imputation of data missing because of graft occlusion or severe disease, the estimated mean (SE) intimal hyperplasia area was 5.11 (0.16) mm2 in supported grafts and 5.79 (0.20) mm2 in unsupported grafts (P = .07). In a sensitivity analysis of 113 patients with both grafts imaged, the mean intimal hyperplasia area was 4.58 (0.18) mm2 and 5.12 (0.23) mm2 in supported and unsupported grafts, respectively (P = .04). By 12 months, 5 patients (2.2%) died and 16 patients (7.1%) experienced a major cardiac or cerebrovascular event. CONCLUSIONS AND RELEVANCE: The 12-month difference in intimal hyperplasia area between supported and unsupported grafts did not achieve statistical significance. Cumulative mortality and major cardiac or cerebrovascular events rates were similar to those in other randomized coronary artery bypass trials. Further investigation to assess the effect of external graft support devices on long-term graft patency and clinical outcomes is warranted. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03209609.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Goldstein DJ, Puskas JD, Alexander JH, et al. External Support for Saphenous Vein Grafts in Coronary Artery Bypass Surgery: A Randomized Clinical Trial. JAMA Cardiol. 2022. PMID: 35675092. doi:10.1001/jamacardio.2022.1437

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。